

The National Academies of
SCIENCES • ENGINEERING • MEDICINE

**Methadone Treatment for Opioid Use Disorder: Examining Federal Regulations and Laws –
A Workshop**

March 3-4, 2022

Workshop Speaker Biographical Sketches

Alan Leshner, Ph.D., (Chair), *please see planning committee biographical sketches.*

Hon. Michael Barrasse is in his 20th year term as a Judge in the 45th Judicial District of the Court of Common Pleas of Lackawanna County, Scranton, Pennsylvania. Prior to taking the bench President Judge Barrasse was elected three terms District Attorney for Lackawanna County. He previously served as a Special Assistant U.S. Attorney, Special Attorney General for the Commonwealth of Pennsylvania and senior trial Assistant District Attorney in Philadelphia. President Judge Barrasse received his B.A. and M.A. in History from the University of Scranton and his J.D. from Dickinson School of Law.



President Judge Barrasse has previously served on the Pennsylvania Supreme Court Disciplinary Board Hearing Panel, the National District Attorneys Association Board of Directors and the Technical Working Group (TWG) of the U.S. Department of Justice.

He also served as chairperson for the Mental Health panel from the PA. Joint State Commission Advisory Committee on Geriatric and Seriously Ill Inmates and President, Pennsylvania Drug Court Professionals. He is presently Chairman, Child Advocacy Center (12 years); Member of the Board of Directors of the Drug and Alcohol Treatment Services (20 years); Northeastern Pennsylvania Red Cross (5 years); Salvation Army (14 years); and Member of the National Judicial College Center of Health and Justice National Judicial Leadership Systems Initiative National Expert Panel (The National Judicial College Center for Health and Justice.)

His present responsibilities include President Judge 45th Judicial District, Administration of the Criminal Docket and the handling of Treatment Courts (Adult, Family, D.U.I., Veterans and Co-occurring). He joined the faculty of the National Judicial College in 2003. He also served as a member of the Pennsylvania Supreme Court Advisory Board on Adult Treatment Courts. President Judge Barrasse is presently on the Board of the National Drug Court; teaches for the National Drug Court, as well as on the National Drug Court Institute Veterans Curriculum Committee for 2010. Judge Barrasse serves as the Judicial Outreach Liaison for Pennsylvania Department of Transportation. He serves as Chairman of the Pennsylvania DUI Oversight Committee and Member of the Pennsylvania Joint State Government Commission Advisory Committee on Addiction Treatment Services. He also presides as a judge on the Court of Judicial Discipline of the Commonwealth of Pennsylvania, which has jurisdiction over all judicial officers in Pennsylvania and must hear and decide formal charges filed against a judicial officer.

Recently, an inductee of the Stanley Goldstein, Drug Court Hall of Fame, which is denoted the highest honor in the Treatment Court field. Additionally, he is a recipient of the Pennsylvania Trial Judges Award for Efficient Caseload Management (Golden Crow Bar Award); the 2006 Pennsylvania Psychological Association Public Service Award; the 2007 John J. Baldi award for excellences in program evaluation and review. (This award promotes the enhancement and development of service and support for persons with mental disabilities). He has also received the Women's Resource Center Public Service Award.

Gavin Bart, M.D., Ph.D., *please see planning committee biographical sketches.*

Richard Bonnie, LLB, *please see planning committee biographical sketches.*

John Brooklyn, M.D., graduated from Brown University Program in Medicine and is Board Certified in Family Medicine and Addiction Medicine. He is an Associate Clinical Professor of Family Medicine and Psychiatry at the University of Vermont Larner College of Medicine and the physician expert in the UVM Center on Rural Addiction. Dr. Brooklyn is the Medical Director of the Howard Center Chittenden Clinic Hub and the Baymark St. Albans Hub. He continues to serve as a Family Physician at Community Health Centers of Burlington.



Dr. Brooklyn has been involved in every UVM buprenorphine research study since 1992. In 2000, he collectively started the nationally recognized CHARM group to coordinate the care of pregnant opioid users and their babies to promote intact families. He helped open five of Vermont's eight methadone programs and was one of the first physicians nationwide to prescribe buprenorphine. Dr. Brooklyn has been a strong advocate for people with substance use disorders to be integrated into medical homes and conceived of the internationally recognized VT Hub and Spoke Model to integrate the treatment of opioid use disorders in the general population. He also helped establish opioid treatment in Vermont prisons, and works on technology solutions to expand access. Dr. Brooklyn is a national mentor for substance use disorder treatment and a trainer for students, residents and faculty members throughout the US. His interests include primary care, interface of behavior and health, promotion of healthy lifestyles, preventative care, treatment of substance use disorders, mindfulness, motivational interviewing and using technological solutions to increase access to opioid agonist treatment.

Robert Brooner, Ph.D., is a Senior Research Scientist at the Friends Research Institute. He was the principal architect of Addiction Treatment Services and Center for Addiction and Pregnancy programs at the Johns Hopkins Bayview Medical Center, along with leading the implementation of the first outpatient substance use disorder treatment service for the NIH-NIDA Intramural Research Center in Baltimore, MD. He has served as PI, Co-PI and Co-Investigator of research grants funded by NIH and other grant-making institutions, and has authored over 150 peer-reviewed publications. Dr. Brooner joined The Johns Hopkins School of Medicine as an Intern in Medical Psychology in 1983 and advanced to tenured professor in 1999, retiring July 2021 as Emeritus Professor. His research focused

on the assessment and treatment of substance use disorder with a focus on the development of adaptive treatment and research approaches using combinations of pharmacologic, psychosocial and behavioral reinforcement interventions, developments of specialized treatment services and programs for pregnant women with substance use disorder (Center for Addiction and Pregnancy), and specialized service approaches for patients with substance use disorder and co-occurring psychiatric problems. He is perhaps best known for his experience and expertise in the development of successful treatment programs providing natural laboratories for the development and testing of new interventions and models of care. His

current work is further expanding the scope of treatment for people with opioid use disorder, including the use of secure electronic pillboxes to enhance the availability and safety of methadone take-home doses, and collaboration with federal agencies and community pharmacies to administer and dispense methadone via prescription from OTP prescribers.

Magdalena Cerdá, DrPH, *please see planning committee biographical sketches.*

Abby Coulter, *please see planning committee biographical sketches.*

Chinazo Cunningham, M.D., is Commissioner of the New York State Office of Addiction Services and Supports (OASAS). She is a physician, researcher, and public health professional who brings over 20 years of expertise in substance use treatment to OASAS. Prior to joining OASAS, she served as the Executive Deputy Commissioner of Mental Hygiene at the New York City Department of Health and Mental Hygiene, was a practicing physician at Montefiore Health System, and a Professor of Medicine, Family and Social Medicine, and Psychiatry and Behavioral Sciences at the Albert Einstein College of Medicine. Dr. Cunningham has more than 20 years' experience in research, care, and program-development that focuses on people who use drugs. She has also partnered with community-based organizations to develop pioneering programs to promote the health of this population. Dr. Cunningham led one of the first clinics in New York City to integrate buprenorphine into primary care. She has trained hundreds of doctors to treat substance use disorders in primary care. She has also led several research studies and published numerous research articles that focus on treating substance use disorders.



Brenda Davis, MSW, is currently employed with a major New York hospital where she has worked in several positions over the past 29 years. Her job as patient advocate affords her the opportunity to provide support to both patients and staff. Being an active member of the administrative staff, puts Ms. Davis in a position of having direct involvement in producing, implementing and supporting agency policy and procedures. Being on the policy and procedure committee and meeting on a regular basis with the patient advisory committee is not only daunting, but what she considers to be her "charge". Ms. Davis' educational background as a MSW and CMA and work history within this field allows her to perform clinical and technical services. She oversees and resolves problems that are not only directly related to the clinic but also when said concerns are within the "care systems" and are inter-related. Ms. Davis is acutely aware of the importance and care of medical records, of patient confidentiality and of staff/patient relations, crisis intervention, conflict resolutions and participation in multidisciplinary case conferences as previously stated. As patient advocate manager, during issues of conflict, she is the one who reviews patient rights and responsibilities, bringing an acute level of individuality, awareness of compliance, appropriateness and coordination of patient care.



Corey Davis, J.D., MSPH, is the deputy director of the Network's Southeastern Region Office and Director of the Harm Reduction Legal Project. He focuses on identifying and leveraging legal and policy initiatives to reduce drug-related harm. He provides expertise and assistance to a wide spectrum of individuals and organizations working to reduce that harm, from federal officials to volunteer-run syringe access programs. Corey has served as chair of a county board of health, chair of the board of the North Carolina Harm Reduction Coalition, and vice-chair of the North Carolina Harm Public Health Foundation, among other positions. He has authored dozens of peer-reviewed articles and holds faculty appointments at the NYU Grossman School of Medicine and Occidental College.



Bridget Dooling, J.D., *please see planning committee biographical sketches.*

Greg Dorchak, J.D., Ph.D., is an Assistant United States Attorney in the U.S. Attorney's Office in Massachusetts, where he enforces federal civil rights statutes, such as the Americans with Disabilities Act, the Fair Housing Act, and the Civil Rights of Institutionalized Persons Act. Much of Dr. Dorchak's work focuses on the rights of individuals with Substance Use Disorder. Prior to this, he enforced fair housing for the U.S. Department of Urban Development. Dr. Dorchak obtained his J.D. from Northeastern University and his Ph.D. from the University of Massachusetts, Amherst.




David Frank, Ph.D., is a Medical Sociologist at New York University's School of Global Public Health. He is also a person who uses drugs and who has been on methadone maintenance treatment for more than 15 years. Dr. Frank's work focuses on opioid use, opioid use treatment programs like medication assisted treatment (MAT), and the structural and legal context that opioid use and treatment occur within. His work specifically examines the role of structural forces, like criminalization and the War on Drugs, in the behaviors, decisions, and outcomes of people who use illegal drugs. Dr. Frank has strong ties to harm reduction and drug-user advocacy groups and uses those relationships to produce research that is both ethically-conducted, and grounded in the real-world experiences of the populations he studies. He is committed to using his position as a scholar to help end the War on Drugs.



Richard Frank, Ph.D., is the Margaret T. Morris Professor of Health Economics emeritus at Harvard Medical School. He is s Senior Fellow in Economic Studies and Director of the Schaeffer Initiative on Health Policy at the Brookings Institution. From 2009 to 2011, he served as the Deputy Assistant Secretary for Planning and Evaluation at DHHS directing the office of Disability, Aging and Long-Term Care Policy. From 2014 to 2016 he served as Assistant Secretary for Planning and Evaluation in the Department of Health and Human Services. His research is focused on the economics of mental health and substance abuse care, long term care financing policy, prescription drug markets, and disability policy. He was elected to the National Academy of Medicine in 1997. He is co-author with Sherry Glied of the book *Better but Not Well* (Johns

Hopkins Press).



Michael French, Ph.D., is Professor and Chair in the Department of Health Management and Policy at the Miami Herbert Business School, University of Miami, with secondary



appointments in the Department of Economics and Department of Public Health Sciences. He is also Director of the Health Economics Research Group, Research Director of the Health Management and Policy Program, and a Senior Fellow of the Center for Health Management and Policy. His research interests and experience includes health economics, health policy, program evaluation, transportation policy, substance abuse research, alternative health care delivery systems, pharmaco-economics, human resource economics, and the economics of crime. He has been principal investigator or project leader on numerous research grants with the National Institutes of Health, the Robert Wood Johnson Foundation, and several state agencies. He is currently editor of the *Journal of Mental Health Policy and Economics*; on the editorial boards for *Health Services Research, Evaluation and Program Planning, Implementation Research and Practice*, and *Journal of Substance Abuse Treatment*; and serves on several research advisory boards for universities, national and international companies, government agencies, and health care organizations. Dr. French has published over 200 peer-reviewed scholarly articles in a variety of multidisciplinary professional journals.

Tracie Gardner, *please see planning committee biographical sketches.*

Walter Ginter serves as Project Director of the Medication Assisted Recovery Support (M.A.R.S.) Project.



He has served as a Project Planning Partner for National Recovery Month, and was a participant in more than twenty federal expert panels and advisory groups since 2001. Mr. Ginter was the recipient of the Richard Lane/Robert Holden Patient Advocacy Award at the 2009 American Association for the Treatment of Opioid Dependence (AATOD) National Conference in NYC, in addition to the 2012 Vernon Johnson America Honors Recovery Award from Faces and Voices of Recovery, the first Lisa Monet-Torres award for MAT Advocacy from FAVOR in 2018, and the Voice Award from SAMHSA in 2018.

Rahul Gupta, M.D., M.P.H., MBA, FACP, is the first medical doctor to serve as the Director of National Drug Control Policy and lead the Office of National Drug Control Policy (ONDCP), a component of the Executive Office of the President. ONDCP coordinates the nation's \$40 billion drug budget and federal policies, including prevention, harm reduction, treatment, recovery support, and supply reduction.



Through his work as a physician, a state and local leader, an educator, and a senior leader of a national nonprofit organization, Dr. Gupta has dedicated his career to improving public health and public safety.

A board-certified internist, Dr. Gupta has been a practicing primary care physician for more than 25 years, and has served in private practice and public health in towns as small as 1,900 residents and cities as large as 25 million. He has served as a local public health official and as the West Virginia Health Commissioner under two governors, where he brought together public health, law enforcement, healthcare, faith-based, business, and other community partners to solve local problems in novel and innovative ways. As the state's Chief Health Officer, he led the opioid crisis response and launched a number of pioneering public health

initiatives, including the Neonatal Abstinence Syndrome Birthscore program to identify high-risk infants, and the groundbreaking statewide Social Autopsy, which examined the lives of overdose victims to determine the factors that led to their deaths and what services could have prevented their deaths. This led the state to expand access to naloxone as well as treatment services including those for incarcerated individuals in order to save lives and help people transition back into society. He supported the expansion of harm reduction programs to more than a dozen sites across the state. He was also instrumental in expanding state-of-the-art, comprehensive and integrative medical and behavioral health programs for pregnant and postpartum women.

His lifelong commitment to educating the next generation of physicians and policymakers has led him to hold academic appointments throughout his career including as a clinical professor in the Department of Medicine at Georgetown University School of Medicine and as visiting faculty at the Harvard University T.H. Chan School of Public Health. Additionally, his passion for global health led him to join the March of Dimes as Chief Medical and Health Officer and Senior Vice President, where he provided strategic oversight for the organization's domestic and global medical and public health efforts.

Dr. Gupta is a national and global thought leader and a driver of innovative public policies who practices what he preaches. He is a buprenorphine-waivered practitioner, providing medication-assisted treatment for people with opioid use disorder. He has been recognized for his career of public service by the American Medical Association, the American Public Health Association, and by *Governing Magazine*, which named him their Public Health Official of the Year in 2018. Additionally, the Pulitzer Prize-winning *Charleston Gazette-Mail* named him as one of its West Virginians of the Year in 2017 for his service to the state. The son of an Indian diplomat, Rahul was born in India and grew up in the suburbs of Washington, D.C. At age 21, he completed medical school at the University of Delhi followed by subspecialty training in pulmonary medicine. He earned a master's degree in public health from the University of Alabama-Birmingham and a global master's of business administration degree from the London School of Business and Finance. He is married to Dr. Seema Gupta, a physician in the Veterans Administration for over a decade. They are the proud parents of identical twin sons, Arka and Drew.

Rebecca Haffajee, J.D., Ph.D., M.P.H., was appointed the Acting Assistant Secretary for Planning and Evaluation (ASPE) and Principal Deputy Assistant Secretary for Planning and Evaluation on March 8, 2021. Before joining ASPE, she was a policy researcher at the RAND Corporation and an assistant professor of health management and policy at the University of Michigan School of Public Health. A lawyer and health policy researcher, Dr. Haffajee's work combines detailed legal analyses with empirical investigations of the relationships between policy and health. Her main research interests are behavioral health, drug policy, and public health policy. She is the recipient of multiple awards, including the AcademyHealth Outstanding Dissertation Award. Her work has been published in the *New England Journal of Medicine*, *Journal of the American Medical Association*, *Annals of Internal Medicine*, *Health Affairs*, and *JAMA Psychiatry* and covered in the *New York Times*, the *Washington Post*, and *National Public Radio*. She received her Ph.D. in Health Policy (concentrating in evaluative sciences and statistics), J.D., and M.P.H. from Harvard. Prior to pursuing health policy research, she practiced health care law at Ropes & Gray LLP, where she advised domestic health care providers on regulatory compliance and reimbursement matters. She also served as a law fellow at the O'Neill Institute for National and Global Health Law at Georgetown University.



Helena Hansen, M.D., Ph.D., please see planning committee biographical sketches.

Ayana Jordan, M.D., Ph.D., is an Addiction Psychiatrist and the Barbara Wilson Associate Professor of Psychiatry in the Department of Psychiatry, at NYU Grossman School of Medicine and Pillar Lead for the Community Engagement in the NYU Langone Institute for Excellence in Health Equity. She is dedicated to creating spaces and opportunities for more people of color, specifically Black women in academia who are vastly underrepresented. The fundamental message of equity and inclusion has informed her research, clinical work and leadership duties at NYU and beyond. For instance, Dr. Jordan was the first Black Associate Program Directors for the Yale Psychiatry Residency, her immediate past academic home, supervising a large group of 64 physicians providing mental health and addiction services throughout Yale medical systems in the state of CT.



She recently became Director of Equity, Diversity and Inclusion for the Justice Community Opioid Innovation Network within the National Institute of Drug (Ab)use, where she'll be working to improve health outcomes for people with opioid use disorder in the carceral system. Dr. Jordan also serves the medical director of Recognizing and Eliminating disparities in Addiction through Culturally informed Healthcare or (REACH), a Substance (Ab)use and Mental Health Services Administration grant, in conjunction with the American Academy of Addiction Psychiatry, geared at increasing the number of addiction specialists from racial and ethnic minoritized populations who obtain training to provide culturally-informed addiction treatment. Passionate about helping racial and ethnic minoritized people achieve wellness and recovery from substance use disorders, Dr. Jordan was fully drawn to community-based research. Dr. Jordan is an NIH-funded researcher where she studies long term outcomes for providing addiction treatment in faith settings. She is elated and inspired to exist in an environment supportive of her vision to work with communities, integrating the cultural and religious aspects of people's lives, while also addressing structural inequities that impede improved mental health and wellness. She is deeply grateful to be taking care of the most historically excluded patients during this time, who are facing extreme challenges in obtaining addiction treatment due to COVID19. Dr. Jordan is the proud recipient of various clinical and research awards and was inducted into the Top 40 under 40 society, by her undergraduate alma mater, Hampton University, a historically Black institution.

Alex Keuroghlian, M.D., M.P.H., is Associate Professor of Psychiatry at Harvard Medical School (HMS) and Director of the Division of Education and Training at The Fenway Institute. He is principal investigator of the National LGBTQIA+ Health Education Center at The Fenway Institute, a HRSA BPHC-funded cooperative agreement to improve care for LGBTQIA+ people across the U.S., as well as the HRSA HAB-funded 2iS Coordinating Center for Technical Assistance. He established the Massachusetts General Hospital Psychiatry Gender Identity Program and is director for two senior courses in sexual and gender minority health at HMS, where he also co-directs the HMS Sexual and Gender Minority Health Equity Initiative, which leads longitudinal medical curriculum and faculty development in sexual and gender minority health. Dr. Keuroghlian also works as clinical psychiatrist focused on mental health and addictions treatment for LGBTQIA+ populations and people living with HIV. He has authored over 80 research articles, review articles, and textbook chapters.



Noa Krawczyk, Ph.D., is an Assistant Professor in the Department of Population Health at NYU School of Medicine and a member of the Center for Opioid Epidemiology and Policy. She



completed her PhD in the Department of Mental Health at the Johns Hopkins Bloomberg School of Public Health, where she studied substance use epidemiology, and previously worked as a Fulbright research scholar to study treatment and health services among cocaine users in Brazil. Her research focuses on studying ways to address barriers to evidence-based treatment for opioid use disorders and improving quality and effectiveness of care, especially among vulnerable groups such as persons with criminal justice involvement. Her work centers on bridging

research and practice by collaborating with health organizations, public health and government agencies and advancing science that can help inform evidence-based policies and practices that reduce harm and promote long term well-being.

Matthew Lawrence, J.D., *please see planning committee biographical sketches.*

Ximena A. Levander, M.D., M.C.R. is an Assistant Professor of Medicine and Clinician Investigator at



Oregon Health & Science University (OHSU) in the Division of General Internal Medicine and Geriatrics, Section of Addiction Medicine. In her current clinical practice, she splits her time working at the OHSU outpatient addiction and complex pain clinic, on the OHSU inpatient addiction consult service (IMPACT), and at a harm reduction low-barrier buprenorphine bridge clinic (HRBR). She is passionate about improving transitions of care for those with substance use disorders.

Her research interests focus on developing and implementing effective interventions for delivering evidence-based substance use disorder treatment in a patient-centered approach to people who use drugs. She is currently funded by a Learning Health Systems Science K12 to evaluate utilization of telemedicine for treatment of opioid use disorder. She is interested in how to ensure equitable access to addiction treatment using telemedicine and how telemedicine could expand access to addiction treatment particularly to those with barriers to care including those living in rural communities. In her free time, she enjoys being outdoors with her partner and her dog in the beautiful Pacific Northwest – hiking, skiing, backpacking. She also enjoys vegetable gardening and recently started painting.

Frances McGaffey, M.P.P., is an officer with Pew's substance use prevention and treatment initiative. In



this role, she leads research on OTP services and efforts to help states use data and metrics to increase access to and utilization of evidence-based treatment. Previously, McGaffey served as a senior associate on Pew's state fiscal health project, where she conducted research on state and local finance and health care in correctional settings. McGaffey holds a bachelor's degree in political science from Vassar College and a master's degree in public policy from the George Washington University.

Valeria Mielke, M.S.W., is the Assistant Commissioner for the New Jersey Division of Mental Health and Addiction Services (DMHAS) in the Department of Human Services and serves as the Single State Agency (SSA) for Substance Abuse and the State Mental Health Authority (SMHA) as designated by the US Substance Abuse and Mental Health Services Administration (SAMHSA). The Division is responsible for the coordination, administration, management and supervision of the community public mental health system, and is also responsible for regulating, monitoring, planning and funding substance abuse prevention, treatment and recovery support services.



Ms. Mielke holds a Bachelor of Arts degree from Fairfield University and a Master of Social Work degree from Rutgers University. Valerie currently serves (as Past President) on the National Association of State Mental Health Program Directors (NASMHPD) Board of Directors and served as President from 2019-2021. NASMHPD's goal is to advance national, state and local mental health policy. Additionally, Valerie serves as a board member of the National Association of State Alcohol and Drug Abuse Directors (NASADAD) Public Policy Committee. NASADAD's goal is to advance national, state and local addiction policy. Valerie was recently appointed to the National Justice Courts Steering Committee which is being led by The Council of State Governments Justice Center. This is a new national consensus-building initiative designed to improve the availability and utility of criminal justice metrics/ data that can drive budget and policy decisions. Valerie also serves on the US DHHS, SAMHSA National Judicial Task Force to Examine State Courts' Response to Mental Illness.

Suzanne Nielsen, BPharmSc[Hons], Ph.D., M.P.S., is the Deputy Director of the Monash Addiction Research Centre at Monash University in Melbourne. She is a current NHMRC Career Development Fellow. She has been a registered pharmacist for over 20 years, with clinical experience in the treatment of substance use disorders in community pharmacy and specialist drug treatment settings in Australia and the United Kingdom. Her research focusses on understanding prescription and over-the-counter drug-related problems, and identifying effective policy and practice interventions to reduced opioid-related and other drug-related harm.



Yngvlid Olsen, M.D., M.P.H., serves as the Acting Director for the Center for Substance Abuse Treatment (CSAT). She has a long history of working within the addiction treatment field to expand access to care and enhance quality. She began her career as the Medical Director for the Johns Hopkins Hospital's outpatient substance use treatment services while a full-time Assistant Professor in the Department of Medicine at the Johns Hopkins School of Medicine. She subsequently served as the Deputy Health Officer for Maryland's Harford County Health Department, where she led a modernization of publicly funded substance use treatment services in collaboration with State and local partners. She next served as the Vice President of Clinical Affairs for the Baltimore Substance Abuse Systems, then the local addiction authority for Baltimore City. In that position, she played a central role in the expansion of buprenorphine treatment for opioid addiction in both specialty treatment and general ambulatory medical systems. Dr. Olsen has also served as Medical Consultant to the Maryland Behavioral Health Administration, as a clinical expert to the Maryland Addiction Consultation Service at the University of Maryland School of Medicine, and as an advisor on addiction interventions to the Baltimore City Health Department. From 2011 to 2021, she served as Medical Director for the Institutes for Behavior Resources/REACH Health Services, a comprehensive outpatient substance use disorder treatment program in Baltimore City.



Dr. Olsen has held numerous senior volunteer leadership positions in the field of addiction medicine. These have included vice president of the American Society of Addiction Medicine, president of the Maryland Association for the Treatment of Opioid Dependence, and president of the Maryland/DC Society of Addiction Medicine. She also has served on the boards of the National Council on Alcohol and Drug Dependence-Maryland, and Stop Stigma Now, and as a clinical expert to the Providers Clinical Support System (PCSS).

After graduating from Harvard Medical School, Dr. Olsen completed residency training in internal medicine and served as primary care chief resident at Boston Medical Center. She completed a Fellowship in General Internal Medicine at Johns Hopkins, during which time she received a Master in Public Health degree from the Johns Hopkins Bloomberg School of Public Health. Dr. Olsen has written and lectured extensively on opioid use disorder and its treatments, the stigma of addiction, the integration of behavioral health and medical care, and clinical and policy solutions to the overdose epidemic. She draws inspiration from the opportunity to provide care for people with substance use disorders as an addiction medicine specialist and general internist.

Kristi O'Malley, J.D., is the current Senior Advisor of the Diversion Control Division within the Drug Enforcement Administration (DEA) and is a 11-year veteran of the Department of Justice. She was appointed to her position as Senior Advisor in January 2022. She serves as the principal advisor to the Administrator of DEA on all matters pertaining to the regulation and coordination of programs associated with the diversion of legally produced controlled substances and listed chemicals. Ms. O'Malley is responsible for overseeing and coordinating major pharmaceutical and chemical diversion investigations; drafting and promulgating regulations; establishing drug production quotas; and conducting liaison with the pharmaceutical industry, international governments, state governments, other federal agencies, and local law enforcement agencies.



Mark Parrino, M.P.A., has been involved in the delivery of health care and substance abuse treatment since 1974. He received both a Baccalaureate in Psychology (1974) and a Masters in Health Policy, Planning and Administration (1982) from New York University. Mr. Parrino served as the Director of the Gramercy Park Medical Group, an outpatient methadone treatment program, from 1980 to 1994. He also served as President of the National Development and Research Institutes, Inc. (NDRI). Mr. Parrino served as the Chair of the Center for Substance Abuse Treatment (CSAT) Consensus Panel for State Methadone Treatment Guidelines, the first Treatment Improvement Protocol (TIP) published for national distribution. Currently, Mr. Parrino is the President of the American Association for the Treatment of Opioid Dependence (AATOD) and continues to be responsible for the development and implementation of the Association's organizing initiatives. He also serves as the Vice President of the World Federation for the Treatment of Opioid Dependence (WFTOD).



Josiah "Jody" Rich, M.D., M.P.H., *please see planning committee biographical sketches.*

Samuel Kelton Roberts, Ph.D., is Associate Professor of History (Columbia University School of Arts & Sciences) and Associate Professor of Sociomedical Sciences (Mailman School of Public Health). He is a former Director of Columbia University's Institute for Research in African American Studies (IRAAS), and also recently has joined Columbia's new Department of African-American and African Diaspora Studies as Associate Professor. Dr. Roberts writes, teaches, and lectures widely the history of public health and medicine, urban history, movements for social justice, African-American history, and on issues of policing and criminal justice. His widely acclaimed book, *Infectious Fear: Politics, Disease, and the Health Effects of Segregation* (UNC Press, 2009), demonstrates the historical and continuing links between racial segregation and poor health outcomes. In 2013-14, Dr. Roberts served as the Policy Director of Columbia University's Justice Initiative, where he coordinated the efforts of several partners to bring attention to the issue of aging and the growing incarcerated elderly population. This work led to the publication of the widely-read landmark report, *Aging in Prison Reducing Elder Incarceration and Promoting Public Safety* (New York: Columbia University Center for Justice. November 2015. (<http://centerforjustice.columbia.edu/policy/aging-in-prison/>)). Roberts is currently researching and writing a book-length project, tentatively titled "To Enter a Society Which Doesn't Want Them": Race, Recovery, and America's Misadventures in Drug Policy. This project explores the social and political evolution of drug addiction rehabilitation and recovery from the beginning of the post-WWII heroin epidemic, to the emergence of methadone maintenance treatment in the 1960s and 1970s, to the search for medico-carceral solutions in the late 1960s and 1970s, and syringe exchange programs (SEPs) and other harm reduction efforts in the 1980s-1990s. He serves or has served on a number of organizational advisory, executive, and editorial boards, including the Alliance of Families for Justice, the Correctional Association of New York, the Legal Action Center, the Bulletin of the History of Medicine, and Modern American History, among others, and is a founding member of the Black Harm Reduction Working Group. Dr. Roberts leads the Research Cluster for the Historical Study of Race, Inequality, and Health at the Columbia University Center for Science and Society, and also is the co-editor of Columbia University Press's book series in Race, Inequality, and Health. In 2018, Dr. Roberts launched the public health and social justice podcast series *People Doing Interesting Stuff* (PDIS). He is also the co-host of the podcast series, *Black Lives: In the Era of COVID-19*, with Mabel O. Wilson.



Rachael Rollins, J.D., LL.M., is the United States Attorney for the District of Massachusetts. Nominated by President Joseph R. Biden on July 26, 2021 and confirmed by the United States Senate on Dec. 8, 2021, Ms. Rollins is the chief federal law enforcement officer for the District of Massachusetts and the first Black woman to hold the position. Prior to her confirmation, Ms. Rollins served as Suffolk County District Attorney (DA) for three years. She was the first woman to ever be elected DA in Suffolk County and the first woman of color to ever hold the position of DA in the Commonwealth of Massachusetts.



Joy Rucker, is originally from New Bedford, MA, a small fishing town south of Boston. Joy began her career in HIV Prevention as an outreach worker in Boston; she was part of the first outreach team to target injecting drug users, encouraging people to get tested for HIV and to not share syringes, years before funding or formal services for people who inject drugs were available. Recognizing the growth of HIV support groups that largely excluded women, people of color, and people who injected drugs, Joy dedicated her time and life to advocating, creating programs, and fighting for all injectors to access to services without barriers.



Joy moved to San Francisco and began working at the Black Coalition on AIDS (BCA), as the program director for a transitional housing program for homeless drug using African Americans -- Rafikiki House. During her tenure at BCA, Rafiki House was awarded the Special Projects of National Significance from HUD. Rafiki House was awarded a contract to train other providers across the country on how to develop similar Housing-First-style programs.

Joy worked for Corporation for Supportive Housing (CSH) and was introduced to Harm Reduction as model of service. While at CSH, she and a team developed the first Harm Reduction Housing training. Also, during that time, she became a trainer for the National Harm Reduction Coalition in New York. After leaving CSH, Joy began work as the Executive Director of the HIV Education and Prevention Project of Alameda County, also known as Casa Segura.

After ten years in that role, Joy moved to Hawaii and created Housing First programs on the islands of Maui and Honolulu.

Joy created the Overdose Prevention Center in Austin, TX for people who inject drugs. She was one of the founders for the Texas Harm Reduction Alliance. The goal is to provide education and NARCAN to injectors, help connect people requesting Medicated Assisted Treatment and other needed services.

Brendan Saloner, Ph.D., is a Bloomberg Associate Professor of American Health in Addiction and



Overdose at Johns Hopkins School of Public Health. Dr. Saloner focuses on access and quality of care for people with substance use disorders. He has an early career award from the National Institute on Drug Abuse to study the role of the Medicaid program in covering treatment of opioid use disorder. He also holds a grant from Arnold Ventures to study the role of state licensure laws in requiring substance use treatment programs to cover medications for opioid use disorder. Dr. Saloner co-leads the evaluation team of the Bloomberg Overdose Initiative, a technical assistance initiative to reduce overdose risk in five states. As part of the Initiative, his team is examining state policies to increase the reach of harm reduction and

opioid use disorder treatment programs. Dr. Saloner has conducted several studies on issues related to opioid use disorder treatment for people in the criminal legal system.

Robert Schwartz, M.D., is a psychiatrist and Senior Research Scientist at the Friends Research Institute.



Through numerous National Institute on Drug Abuse (NIDA) grant awards, he has led services research on treatment of opioid use disorder in the community and in corrections. He was Chair of SAMHSA's Treatment Improvement Protocol (TIP 63) on Medications for Opioid Use Disorder and received the Nyswander Dole Award from the American Association for the Treatment of Opioid Dependence. Many of Dr Schwartz's over 200 scientific publications are focused on methadone treatment. He is currently the Principal Investigator of several NIDA-funded studies.

Jane “Janie” Sheridan, Ph.D., is an Associate Director of the Centre for Addiction Research, at the University of Auckland, New Zealand. After completing her Bachelor of Pharmacy Degree at the University of Bath, UK, she completed her PhD at the University of London, UK in 1995. Janie has held teaching and research positions at the School of Pharmacy, London University, the National Addiction Centre, the Institute of Psychiatry, King's College London, and since 2002 has held an academic position at the School of Pharmacy, the University of Auckland since 2002, as Associate Professor, then Professor. Janie's research is in the disciplines of addictions, and social pharmacy/pharmacy practice. Her



pharmacy and primary care research has focused on pharmacy roles in youth health, medicines sharing, harm reduction service provision through primary care, health literacy, and cultural competence. Her addictions research has included new psychoactive substances, pharmaceutical drug misuse, primary health care issues for drug users and their access to healthcare services, methadone prescribing patterns, community pharmacy services for injecting drug users, the role of community pharmacy in screening and brief interventions for risky drinkers, older adults alcohol consumption, community pharmacy smoking cessation interventions, and treatment for stimulant dependence. She has also been involved in health professional education and postgraduate training in the management of opioids dependence, and health issues related to substance misuse.

Kenneth Stoller, M.D., *please see planning committee biographical sketches.*

Mishka Terplan, M.D., is board certified in both obstetrics and gynecology and in addiction medicine. His primary clinical, research, and advocacy interests lie along the intersections of reproductive and behavioral health. He is Medical Director at Friends Research Institute and adjunct faculty at the University of California, San Francisco where he is a Substance Use Warmline clinician for the National Clinician Consultation Center. Dr. Terplan has active grant funding and has published over 130 peer-reviewed articles with emphasis on health inequities, discrimination, and access to treatment. He has spoken at local high schools and before the United States Congress and has participated in expert panels at CDC, SAMHSA, ONDCP, OWH, FDA, and NIH primarily on issues related to gender and addiction.



Kamilla Venner, Ph.D., is a member of the Ahtna Athabascan tribe, an Associate Professor of Psychology at the University of New Mexico, and a clinical psychologist. Her research aims to reduce the disproportionate substance use related health inequities American Indian/Alaska Native (AI/AN) people experience. She has been awarded highly competitive NIH funding to conduct her work with total funding as PI or Co-I of \$32,486,973 (\$13,474,412 as PI). She has also served as a consultant for many other grants (total funding nearly \$38,500,000), both national and international, focused on health inequities with AI/AN and Indigenous populations. Her programmatic line of research has centered on four lines of inquiry. First, she has tested the psychometric properties of measures to ensure validity and reliability with AI/AN people and to highlight areas of universality versus cultural specificity. Second, she explores models and dimensions to systematically culturally tailored evidence-based treatments (EBTs) to improve acceptability, engagement, retention, and outcomes for AI/AN people. Third, she conducts randomized controlled trials (RCTs) with AI/AN participants. These RCTs allow examination of substance use outcomes and other indicators of well-being in addition to moderators and mediators to better understand active mechanisms of the culturally tailored EBTs and patient characteristics that may predict outcomes. Her expertise in



motivational interviewing with Indigenous populations has crossed fields of substance use treatment, improving oral health care, and increasing student engagement in learning about diversity and multiculturalism. Most recently, she is testing culturally centered implementation models to improve adoption of EBTs, such as medication treatment for opioid use disorder, and screening of comorbid chronic pain and opioid misuse/opioid use disorder in AI/AN programs and communities.

Alexander Y. Walley, M.D., M.Sc., is Professor of Medicine at Boston University School of Medicine and a



general internist and addiction medicine specialist at Boston Medical Center. He is the director of the Grayken Addiction Medicine Fellowship program since 2011. His research focuses on the medical complications of substance use, specifically HIV and overdose. For the NIH-funded HEALing Communities Study - Massachusetts, he is the Care Continuum Core Director. He provides primary care and office-based addiction treatment for patients with HIV at Boston Medical Center. He is the medical director for the Massachusetts Department of Public Health's Opioid

Overdose Prevention Program. He founded BMC's inpatient Addiction Consult Service in 2015 and the Faster Paths low-barrier access clinic in 2016. He previously was a site medical director for opioid treatment programs in Boston from 2007 to 2016. He is president-elect of the American College of Academic Addiction Medicine.

Emily Wang, M.D., is a professor in the Yale School of Medicine and Public Health and directs the



SEICHE Center for Health and Justice. The SEICHE Center is a collaboration between the Yale School of Medicine and Yale Law School working to stimulate community transformation by identifying the legal, policy, and practice levers that can improve the health of individuals and communities impacted by mass incarceration. She leads the Health Justice Lab research program, which receives National Institutes of Health funding to investigate how incarceration influences chronic health conditions, including cardiovascular disease, cancer, and opioid use disorder, and uses a participatory approach to study interventions which prevent and mitigate the

impacts of incarceration. As an internist, she has cared for thousands of individuals with a history of incarceration and is co-founder of the Transitions Clinic Network, a consortium of 50 community health centers nationwide dedicated to caring for individuals recently released from correctional facilities by employing community health workers with histories of incarceration. Dr. Wang serves on the World Health Organization Health In Prisons Programme Steering Committee and co-chaired the National Academy of Sciences, Engineering, and Medicine committee on "Decarcerating Correctional Facilities During COVID-19: Advancing Health, Equity, and Safety (2020)." Her work been published in the Lancet, JAMA, American Journal of Public Health, and Health Affairs and showcased in national outlets such as the New York Times, NPR, and CNN. Dr. Wang has an AB from Harvard University, an MD from Duke University, and a MAS from the University of California, San Francisco.

Shelly Weizman, J.D., is a human rights lawyer whose areas of interest include advancing public policy related to addiction, mental health, and disabilities. She currently serves as the Associate Director of the Addiction and Public Policy Initiative at the O'Neill Institute for National and Global Health Law at Georgetown University Law Center where she works on a project portfolio focused on the overdose epidemic and how the law can promote access to treatment and support recovery. Ms. Weizman is an Adjunct Professor at Georgetown Law, where she introduced and teaches a course on Addiction & Mental Health Law and Policy. She is on the leadership team that developed a new Master of Science in Addiction Policy & Practice at Georgetown University Graduate School of Arts & Sciences. She also facilitates the Recovery Policy Collaborative, a network of experts in health, human rights, policy and government who have lived experience with addiction and serves on the Board of Directors of Faces and Voices of Recovery. Ms. Weizman previously served as the Assistant Secretary for Mental Hygiene in the Office of the Governor of New York where she oversaw policy and operations related to addiction, mental health and disabilities. She began her legal career as a civil rights attorney at MFY Legal Services, a not-for-profit legal services organization in New York City. She holds a JD with a concentration in Health Law and Policy from Seton Hall University School of Law. She is also a person in long-term recovery from a substance use disorder, celebrating more than 24 years of recovery.



Li-Tzy Wu, R.N., Sc.D., M.A., is a Professor in the Department of Psychiatry and Behavioral Sciences and the Department of Medicine. Dr. Wu received pre- and post-doctoral training in Psychiatric and Addiction Epidemiology from the Johns Hopkins University. She is the Principal Investigator of two clinical trials on community pharmacist-provided care services for medication treatment for opioid use disorder (MOUD) (i.e., buprenorphine, pharmacy administration and dispensing of methadone) that involve the use of a physician-pharmacist collaborative care model (Wu et al., 2021; Wu et al., 2022).

